BOSTON–(BUSINESS WIRE)–The Sync Project, a clinical-stage company focused on developing music as personalized medicine, today announced the appointments of four world-renowned musical artists to its Advisory Board. The new advisors – Rock and Roll Hall of Famer Peter Gabriel; Grammy Award-winning alternative artist, Annie Clark (St. Vincent); critically acclaimed electronic musician, Mercury Music Prize and Ivor Novello nominee, Jon Hopkins; distinguished composer and conductor, Esa-Pekka Salonen – will collaborate with the Sync Project on product strategy. The Company also announced the appointment of former Biogen Idec Executive Vice President and Millennium Pharmaceuticals Chief Business Officer, Steven Holtzman, to its Board of Directors. read more
Supervised Autonomous In Vivo Robotic Surgery on Soft Tissues is Feasible and Outperforms Standard Surgery Techniques According to Study from the Sheikh Zayed Institute for Pediatric Surgical Innovation at Children’s National Health System
PRNewswire-USNewswire/ — Surgeons and scientists from the Sheikh Zayed Institute for Pediatric Surgical Innovation at Children’s National Health System are the first to demonstrate that supervised, autonomous robotic soft tissue surgery on a live subject (in vivo) in an open surgical setting is feasible and outperforms standard clinical techniques in a dynamic clinical environment.
The study, published today in Science Translational Medicine, reports the results of soft tissue surgeries conducted on both inanimate porcine tissue and living pigs using proprietary robotic surgical technology, Smart Tissue Autonomous Robot (STAR), developed at Children’s National. This technology removes the surgeon’s hands from the procedure, instead utilizing the surgeon as supervisor, with soft tissue suturing autonomously planned and performed by the STAR robotic system. read more
FDA Grants Priority Review for Lilly’s Olaratumab, an Investigational Medicine for Advanced Soft Tissue Sarcoma
PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the biologics license application (BLA) for olaratumab, a PDGFRα antagonist, in combination with doxorubicin, for the potential treatment of people with advanced soft tissue sarcoma (STS) not amenable to curative treatment with radiotherapy or surgery.
Lilly has received additional designations for olaratumab from the FDA, including Breakthrough Therapy, Fast Track and Orphan Drug, for this indication. According to the FDA, Breakthrough Therapy designation is a process designed to expedite the development of a potential medicine that is intended to treat a serious condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint. read more
Bloodstream infection pathogens becoming more resilient
A recently published special issue of Virulence , ” Bloodstream Infections “, focuses on the resilience of bloodstream infections (BSI) and is endorsed by the European Study Group for Infections in Compromised Hosts of the European Society of Clinical Microbiology and Infectious Diseases . Guest Editor Dr. Claudio Viscoli, a Professor of Infectious Disease at the University of Genoa, outlines in an editorial ” Bloodstream Infections: The Peak of the Iceberg ” why a special issue was created focusing extensively on BSI. read more
Nordic Nanovector announces first patient enrolled in Arm 3 of expanded Phase 1/2 study of Betalutin® in NHL patients
Nordic Nanovector ASA (OSE: NANO), a biotechnology company focusing on the development of novel targeted therapeutics in haematology and oncology, announces that the first patient has been enrolled into one of the two new arms of its expanded Lymrit 37-01 clinical study with Betalutin®.
Betalutin® is a novel anti-CD37 targeting Antibody Radionuclide Conjugate in development for the treatment of major types of non-Hodgkin’s lymphoma (NHL), including Follicular Lymphoma (FL). read more
Cook Medical Issues Global, Voluntary Recall of Catheters with Beacon Tip Technology
On April 15, 2016, Cook Medical initiated a voluntary recall of 4,146,309 catheters with Beacon® Tip technology. Catheters with Beacon Tip technology have been found to exhibit polymer degradation of the catheter tip, resulting in tip fracture and/or separation, which have resulted in 30 Medical Device Reports to date. read more
Medtronic Welcomes Karen L. Parkhill as Its New Chief Financial Officer
Medtronic plc (NYSE: MDT) announced today the appointment of Karen L. Parkhill as executive vice president and chief financial officer (CFO), effective June 20, 2016. Parkhill will succeed Gary L. Ellis in the CFO role and will report to Medtronic CEO Omar Ishrak.
Today’s announcement concludes an external search process conducted by the company to ensure a seamless succession of the CFO portion of Ellis’s current responsibilities. As part of his planned succession, Ellis will remain on the Medtronic Executive Committee, assist with the transition of the CFO office, and will continue to lead the other key functions within his portfolio of responsibilities until his retirement. read more
AmerisourceBergen Announces Three Year Extension of Strategic, Long-Term Relationship with Walgreens Boots Alliance
VALLEY FORGE, Pa.–(BUSINESS WIRE)–AmerisourceBergen (NYSE:ABC) today announced that it has extended the term of its strategic, long-term relationship with Walgreens Boots Alliance, Inc. for an additional three years. As a result, both the pharmaceutical distribution contract and the Walgreens Boots Alliance Development (WBAD) relationship have been extended to 2026. The extension includes an enhanced commitment from Walgreens Boots Alliance to utilize AmerisourceBergen as its key U.S. distribution partner, and AmerisourceBergen has agreed to make certain working capital investments in the relationship and will proceed with additional capital investments in its distribution network.
Alvogen Launches First Generic Equivalent of Zoladex
- Only approved generic to Zoladex in regulated markets
- Complements a fast growing complex product pipeline in the region
- Provides compelling cost saving opportunities to patient read more
Egalet Announces Scientific Presentations at American Pain Society Meeting
–Data demonstrate ARYMO™ ER has a strong abuse-deterrent profile and does not dose dump in the presence of alcohol —
PRNewswire/ — Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, announced today that researchers will present three scientific posters at the 35th Annual American Pain Society meeting May 11 to 14, 2016 in Austin, TX for ARYMO™ ER (morphine sulfate) extended-release tablets, an abuse-deterrent, oral morphine product candidate. read more